Targeting Toll-like receptor signaling as a novel approach to prevent ocular infectious diseases

Indian Journal of Medical Research

Volumn 138, Issue NOV, 2013, Pages 609-619

  Pandey, Rajeev K ^a   Yu, Fu Shin ^a,b   Kumar, Ashok ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; NF kB; Ocular immune privilege; Ocular surface; Proinflammatory cytokines; TLR signaling; Toll like receptors

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDINE RELATED ANTIMICROBIAL PEPTIDE; CONTACT LENS SOLUTION; ERITORAN; FLAGELLIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; LIGAND; MYELOID DIFFERENTIATION FACTOR 88; NEUTRALIZING ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PAM3CYS; POLYPEPTIDE ANTIBIOTIC AGENT; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; UNCLASSIFIED DRUG; INTERLEUKIN 1; INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL KERATITIS; BLOOD EYE BARRIER; DIMERIZATION; ENDOPHTHALMITIS; GENE SILENCING; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; RETINA NERVE CELL; REVIEW; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; ADAPTIVE IMMUNITY; CONFORMATIONAL TRANSITION; CYTOKINE PRODUCTION; INFECTION PREVENTION; PATHOGENESIS; PROTEIN FUNCTION;

CORNEA; ENDOPHTHALMITIS; EYE INFECTIONS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; KERATITIS; MOLECULAR TARGETED THERAPY; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84891702527     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Selinger DS, Selinger RC, Reed WP. Resistance to infection of the external eye: the role of tears. Surv Ophthalmol 1979; 24: 33-8.
2. Bron AJ, Seal DV. The defences of the ocular surface. Trans Ophthalmol Soc UK 1986; 105: 18-25.
3. Bron AJ. Eyelid secretions and the prevention and production of disease. Eye (Lond) 1988; 2: 164-71.
4. Pleyer U, Baatz H. Antibacterial protection of the ocular surface. Ophthalmologica 1997; 211 (Suppl 1): 2-8.
5. Smolin G. The defence mechanism of the outer eye. Trans Ophthalmol Soc UK 1985; 104: 363-6.
6. Gachon AM, Lacazette E. Tear lipocalin and the eye's front line of defence. Br J Ophthalmol 1998; 82: 453-5.
7. Baum JL. Current concepts in ophthalmology. Ocular infections. N Engl J Med 1978; 299: 28-31.
8. Ueta M, Kinoshita S. Ocular surface inflammation mediated by innate immunity. Eye Contact Lens 2010; 36: 269-81.
9. Maltseva IA, Fleiszig SM, Evans DJ, Kerr S, Sidhu SS, McNamara NA, et al. Exposure of human corneal epithelial cells to contact lenses in vitro suppresses the upregulation of human beta-defensin-2 in response to antigens of Pseudomonas aeruginosa. Exp Eye Res 2007; 85: 142-53.
10. Cohen M, Montgomerie JZ. Hematogenous endophthalmitis due to Candida tropicalis: report of two cases and review. Clin Infect Dis 1993; 17: 270-2.
11. Akpek EK, Gottsch JD. Immune defense at the ocular surface. Eye (Lond) 2003; 17: 949-56.
12. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
13. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 2004; 6: 1382-7.
14. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16: 637-46.
15. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-35.
16. Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 2006; 90: 103-8.
17. Kurpakus-Wheater M, Kernacki KA, Hazlett LD. Maintaining corneal integrity how the "window" stays clear. Prog Histochem Cytochem 2001; 36: 185-259.
18. Mantelli F, Argueso P. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol 2008; 8: 477-83.
19. Hazlett LD. Corneal response to Pseudomonas aeruginosa infection. Prog Retin Eye Res 2004; 23: 1-30.
20. Glasgow BJ, Marshall G, Gasymov OK, Abduragimov AR, Yusifov TN, Knobler CM. Tear lipocalins: potential lipid scavengers for the corneal surface. Invest Ophthalmol Vis Sci 1999; 40: 3100-7.
21. Gasymov OK, Abduragimov AR, Yusifov TN, Glasgow BJ. Interaction of tear lipocalin with lysozyme and lactoferrin. Biochem Biophys Res Commun 1999; 265: 322-5.
22. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-33.
23. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549.
24. Dallegri F, Ottonello L. Tissue injury in neutrophilic inflammation. Inflamm Res 1997; 46: 382-91.
25. Koevary SB. Ocular immune privilege: a review. Clin Eye Vis Care 2000; 12: 97-106.
26. Jager MJ, Gregerson DS, Streilein JW. Regulators of immunological responses in the cornea and the anterior chamber of the eye. Eye (Lond) 1995; 9: 241-6.
27. Taylor AW. The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J Neuroimmunol 2005; 162: 43-50.
28. Ferguson TA, Waldrep JC, Kaplan HJ. The immune response and the eye. II. The nature of T suppressor cell induction in anterior chamber-associated immune deviation (ACAID). J Immunol 1987; 139: 352-7.
29. Ferguson TA, Kaplan HJ. The immune response and the eye. I. The effects of monoclonal antibodies to T suppressor factors in anterior chamber-associated immune deviation (ACAID). J Immunol 1987; 139: 346-51.
30. Stein-Streilein J. Immune regulation and the eye. Trends Immunol 2008; 29: 548-54.
31. Beyer TL, Vogler G, Sharma D, O'Donnell FE, Jr. Protective barrier effect of the posterior lens capsule in exogenous bacterial endophthalmitis-an experimental primate study. Invest Ophthalmol Vis Sci 1984; 25: 108-12.
32. Whiston EA, Sugi N, Kamradt MC, Sack C, Heimer SR, Engelbert M, et al. Alpha B-crystallin protects retinal tissue during Staphylococcus aureus-induced endophthalmitis. Infect Immun 2008; 76: 1781-90.
33. Haynes RJ, McElveen JE, Dua HS, Tighe PJ, Liversidge J. Expression of human beta-defensins in intraocular tissues. Invest Ophthalmol Vis Sci 2000; 41: 3026-31.
34. Engelbert M, Gilmore MS. Fas ligand but not complement is critical for control of experimental Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 2005; 46: 2479-86.
35. Yu FS, Hazlett LD. Toll-like receptors and the eye. Invest Ophthalmol Vis Sci 2006; 47: 1255-63.
36. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004; 5: 971-4.
37. Bowie A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000; 67: 508-14.
38. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
39. Yamamoto M, Takeda K, Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 2004; 40: 861-8.
40. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-25.
41. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32: 305-15.
42. Wetzler LM. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine 2003; 21 (Suppl 2): S55-60.
43. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009; 31: 873-84.
44. von Aulock S, Schroder NW, Gueinzius K, Traub S, Hoffmann S, Graf K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188: 938-43.
45. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000; 12: 20-6.
46. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-103.
47. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005; 174: 2942-50.
48. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-8.
49. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-31.
50. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-9.
51. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
52. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004; 101: 3516-21.
53. Muzio M, Mantovani A. Toll-like receptors. Microbes Infect 2000; 2: 251-5.
54. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95.
55. Kumar A, Yu FS. Toll like receptors and corneal innate immunity. Curr Mol Med 2006; 6: 327-37.
56. Ueta M, Nochi T, Jang MH, Park EJ, Igarashi O, Hino A, et al. Intracellularly expressed TLR2s and TLR4s contribution to an immunosilent environment at the ocular mucosal epithelium. J Immunol 2004; 173: 3337-47.
57. Zhang J, Kumar A, Wheater M, Yu FS. Lack of MD-2 expression in human corneal epithelial cells is an underlying mechanism of lipopolysaccharide (LPS) unresponsiveness. Immunol Cell Biol 2009; 87: 141-8.
58. Kumar A, Zhang J, Yu FS. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology 2006; 117: 11-21.
59. Zhang J, Xu K, Ambati B, Yu FS. Toll-like receptor 5-mediated corneal epithelial inflammatory responses to Pseudomonas aeruginosa flagellin. Invest Ophthalmol Vis Sci 2003; 44: 4247-54.
60. Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol 2010; 42: 495-505.
61. Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010; 48: 1121-32.
62. Magone MT, Whitcup SM. Mechanisms of intraocular inflammation. Chem Immunol 1999; 73: 90-119.
63. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond) 1995; 9: 236-40.
64. Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol 1979; 23: 279-96.
65. Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, Peng B, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res 1997; 49: 268-80.
66. Worthylake RA, Burridge K. Leukocyte transendothelial migration: orchestrating the underlying molecular machinery. Curr Opin Cell Biol 2001; 13: 569-77.
67. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
68. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004; 4: 432-44.
69. Ming WJ, Bersani L, Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol 1987; 138: 1469-74.
70. Smart SJ, Casale TB. Pulmonary epithelial cells facilitate TNF-alpha-induced neutrophil chemotaxis. A role for cytokine networking. J Immunol 1994; 152: 4087-94.
71. Crane IJ, Liversidge J. Mechanisms of leukocyte migration across the blood-retina barrier. Semin Immunopathol 2008; 30: 165-77.
72. Petropoulos IK, Vantzou CV, Lamari FN, Karamanos NK, Anastassiou ED, Pharmakakis NM. Expression of TNF-alpha, IL-1beta, and IFN-gamma in Staphylococcus epidermidis slime-positive experimental endophthalmitis is closely related to clinical inflammatory scores. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1322-8.
73. Shechter R, Ronen A, Rolls A, London A, Bakalash S, Young MJ, et al. Toll-like receptor 4 restricts retinal progenitor cell proliferation. J Cell Biol 2008; 183: 393-400.
74. Bonini S, Micera A, Iovieno A, Lambiase A. Expression of Toll-like receptors in healthy and allergic conjunctiva. Ophthalmology 2005; 112: 1528.
75. Hayashi T, Raz E. TLR9-based immunotherapy for allergic disease. Am J Med 2006; 119: 897. e1-6.
76. Woehrle T, Du W, Goetz A, Hsu HY, Joos TO, Weiss M, et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008; 41: 322-9.
77. Khatri S, Lass JH, Heinzel FP, Petroll WM, Gomez J, Diaconu E, et al. Regulation of endotoxin-induced keratitis by PECAM-1, MIP-2, and toll-like receptor 4. Invest Ophthalmol Vis Sci 2002; 43: 2278-84.
78. Hise AG, Gillette-Ferguson I, Pearlman E. Immunopathogenesis of Onchocerca volvulus keratitis (river blindness): a novel role for TLR4 and endosymbiotic Wolbachia bacteria. J Endotoxin Res 2003; 9: 390-4.
79. Hall LR, Pearlman E. Pathogenesis of onchocercal keratitis (River blindness). Clin Microbiol Rev 1999; 12: 445-53.
80. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980; 286: 611-3.
81. Li Q, Peng B, Whitcup SM, Jang SU, Chan CC. Endotoxin induced uveitis in the mouse: susceptibility and genetic control. Exp Eye Res 1995; 61: 629-32.
82. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009; 30: 475-87.
83. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005; 26: 469-76.
84. Gao N, Kumar A, Jyot J, Yu FS. Flagellin-induced corneal antimicrobial peptide production and wound repair involve a novel NF-kappaB-independent and EGFR-dependent pathway. PLoS One 2010; 5: e9351.
85. Kumar A, Gao N, Standiford TJ, Gallo RL, Yu FS. Topical flagellin protects the injured corneas from Pseudomonas aeruginosa infection. Microbes Infect 2010; 12: 978-89.
86. Kumar A, Hazlett LD, Yu FS. Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of Pseudomonas aeruginosa keratitis. Infect Immun 2008; 76: 89-96.
87. Kumar A, Singh CN, Glybina IV, Mahmoud TH, Yu FS. Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitis. J Infect Dis 2010; 201: 255-63.
88. Callegan MC, Booth MC, Jett BD, Gilmore MS. Pathogenesis of gram-positive bacterial endophthalmitis. Infect Immun 1999; 67: 3348-56.
89. Kochan T, Singla A, Tosi J, Kumar A. Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus. Infect Immun 2012; 80: 2076-88.
90. Varma TK, Durham M, Murphey ED, Cui W, Huang Z, Lin CY, et al. Endotoxin priming improves clearance of Pseudomonas aeruginosa in wild-type and interleukin-10 knockout mice. Infect Immun 2005; 73: 7340-7.
91. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61: 177-97.
92. Yu FS, Cornicelli MD, Kovach MA, Neiostead MW, Zeng X, Kumar A, et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 2010; 185: 1142-9.
93. Hickey EJ, You X, Kaimaktchiev V, Stenzel-Poore M, Ungerleider RM. Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg 2007; 133: 1588-96.
94. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke 2004; 35: 2576-81.
95. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, et al. Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2008; 28: 1040-7.